PVH
KROS icon

Psagot Value Holdings’s Keros Therapeutics KROS Stock Holding History

Psagot Value Holdings’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,772
Closed -$110K – 418
2021
Q3 		$110K Sell
2,772
-54,198
-95% -$1.93M 0.02% 297
2021
Q2 		$2.42M Buy
+56,970
New +$3.09M 0.09% 104

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Psagot Value Holdings's KROS Position: Q4 2021 in Review

Psagot Value Holdings sold out of Keros Therapeutics (KROS) in Q4 2021, closing a stake of 2,772 shares — an estimated $110K sold.

Psagot Value Holdings first reported a position in KROS in Q2 2021 and held it in 2 quarters. The position peaked at $2.42M in Q2 2021. 99 funds tracked by Wall St. Rank hold KROS as of Q4 2021.

  • Psagot Value Holdings reported no remaining Keros Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Psagot Value Holdings sold 2,772 Keros Therapeutics shares in Q4 2021, an estimated $110K.
  • Psagot Value Holdings first reported a position in Keros Therapeutics in Q2 2021 and held it in 2 quarters.
  • Psagot Value Holdings's Keros Therapeutics position peaked at $2.42M in Q2 2021.
  • 99 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2021.

Based on Psagot Value Holdings's 13F filing for Q4 2021, filed 14 Mar 2022.